Conventional random-effects models in meta-analysis rely on large sample approximations instead of exact small sample results. While random-effects methods produce efficient estimates and confidence intervals for the summary effect have correct coverage when the number of studies is sufficiently large, we demonstrate that conventional methods…

Checking for possible inconsistency between direct and indirect evidence is an important task in network meta-analysis. Recently, an evidence-splitting (ES) model has been proposed, that allows separating direct and indirect evidence in a network and hence assessing inconsistency. A salient feature of this model is that the variance for…

Meta-analyses have become the gold standard for synthesizing evidence from multiple clinical trials, and they are especially useful when outcomes are rare or adverse since individual trials often lack sufficient power to detect a treatment effect. However, when zero events are observed in one or both treatment arms in a trial, commonly used…

The "LFK" index has been promoted as an improved method to detect bias in meta-analysis. Putatively, its performance does not depend on the number of studies in the meta-analysis. We conducted a simulation study, comparing the "LFK" index test to three standard tests for funnel plot asymmetry in settings with smaller or larger…

Background: Traditionally, meta-analysis of time-to-event outcomes reports a single pooled hazard ratio assuming proportional hazards (PH). For health technology assessment evaluations, hazard ratios are frequently extrapolated across a lifetime horizon. However, when treatment effects vary over time, an assumption of PH is not always valid. The…

This study builds on the simulation framework of a recent paper by Stanley and Doucouliagos ("Research Synthesis Methods" 2023;14;515--519). S&D use simulations to make the argument that meta-analyses using partial correlation coefficients (PCCs) should employ a "suboptimal" estimator of the PCC standard error when…

Drug repurposing refers to the process of discovering new therapeutic uses for existing medicines. Compared to traditional drug discovery, drug repurposing is attractive for its speed, cost, and reduced risk of failure. However, existing approaches for drug repurposing involve complex, computationally-intensive analytical methods that are not…